Go Pro
NASDAQ:CSBR

Champions Oncology Q1 2027 Earnings Report

Champions Oncology logo
$5.22 -0.06 (-1.14%)
As of 09/4/2026 04:00 PM Eastern

Champions Oncology EPS Results

Actual EPS
N/A
Consensus EPS
-$0.01
Beat/Miss
N/A
One Year Ago EPS
N/A

Champions Oncology Revenue Results

Actual Revenue
N/A
Expected Revenue
$15.05 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Champions Oncology Announcement Details

Quarter
Q1 2027
Time
After Market Closes
Conference Call Date
Thursday, September 10, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Champions Oncology Earnings Headlines

The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
See More Champions Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Champions Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Champions Oncology and other key companies, straight to your email.

About Champions Oncology

Champions Oncology (NASDAQ:CSBR) engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

View Champions Oncology Profile